DNA Methylation Status of WNT Antagonist SFRP5 Can Predict the Response to the EGFR-tyrosine Kinase Inhibitor Therapy in Non-Small Cell Lung Cancer

Journal of Experimental and Clinical Cancer Research - United Kingdom
doi 10.1186/1756-9966-31-80
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Springer Science and Business Media LLC

Related search

Does the Efficacy of Epidermal Growth Factor Receptor (EGFR) Tyrosine Kinase Inhibitor Differ According to the Type of EGFR Mutation in Non-Small Cell Lung Cancer?

Korean Journal of Internal Medicine
Internal Medicine
2017English

JCES 01.18 Uncommon Mutation Types of EGFR and Response to EGFR Tyrosine Kinase Inhibitors in Chinese Non-Small Cell Lung Cancer Patients

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2017English

Intrinsic Resistance to EGFR Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer With Activating EGFR Mutations

OncoTargets and Therapy
OncologyPharmacology
2016English

Pretreatment Epidermal Growth Factor Receptor (EGFR) T790M Mutation Predicts Shorter EGFR Tyrosine Kinase Inhibitor Response Duration in Patients With Non–Small-Cell Lung Cancer

Journal of Clinical Oncology
Cancer ResearchMedicineOncology
2012English

Development and Validation of a Model to Predict Tyrosine Kinase Inhibitor-Sensitive EGFR Mutations of Non-Small Cell Lung Cancer Based on Multi-Institutional Data

Thoracic Cancer
MedicinePulmonaryRespiratory MedicineOncology
2018English

MA18.05 Characteristics and Long-Term OS of Non-Small Cell Lung Cancer Patients Receiving EGFR Tyrosine Kinase Inhibitor Treatment

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

Concurrent Genetic Alterations Predict the Progression to Target Therapy in EGFR-mutated Advanced Non-Small Cell Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2019English

Non-Small Cell Lung Cancer-Small Cell Lung Cancer Transformation as Mechanism of Resistance to Tyrosine Kinase Inhibitors in Lung Cancer

2020English

ALK, ROS1 and EGFR Next-Generation Tyrosine Kinase Inhibitors in Advanced Non-Small-Cell Lung Cancer

Oncology in Clinical Practice
Oncology
2019English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy